AzurRx BioPharma price target raised to $8 from $6 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised his price target for AzurRx BioPharma to $8 after the company announced that the Phase 2a trial of MS1819 in chronic pancreatitis patients with exocrine pancreatic insufficiency met both primary and secondary endpoints. Importantly, the efficacy demonstrated by MS1819 is comparable to that of the porcine-derived pancrelipase currently on the market, such as Creon, Selvaraju tells investors in a research note. He views the data as “very encouraging” and reiterates a Buy rating on AzurRx.
https://thefly.com/landingPageNews.php?id=2794981